Allergy Therapeutics plc·Healthcare

Amazon.com Inc (NASDAQ:AMZN) and Delta Air Lines Inc (NYSE:DAL) have announced a new multi-year agreement aimed at enhancing in-flight internet connectivity...

A successful rollout of its newly launched grass-pollen treatment is ste put Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) on the path to...

A successful rollout of its newly launched grass-pollen treatment is ste put Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) on the path to self-sustaining profitability. That's according to Cavendish, the AIM-listed biotech's house broker, which cites management's previous commentary around peak sales potential of €100 million in Germany alone in a global market projected to reach around $1 billion by 2030.

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the immunotherapy company, expects commercial momentum to build through the second half of its financial year as its newly launched Grassmuno grass pollen treatment gains traction in Germany, while planning advances for a phase IIb trial of its short-course peanut allergy vaccine candidate. Grassmuno, an injected grass pollen allergen immunotherapy that received German regulatory approval during the period, launched in January 2026 and has seen a strong early response from prescribing clinicians, with the company describing it as an expected major driver of revenue in its largest market.

8:15am: Cooling tensions US stocks were set for a strong open on Tuesday as easing geopolitical tensions lifted sentiment. Dow Jones and S&P 500 futures...

General Mills Inc (NYSE:GIS, XETRA:GRM) shares remain under pressure as it faces continued volume declines in North America Retail (NAR) and limited...
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Healthcare
Drug Manufacturers - Specialty & Generic
612
2010-02-03
0.89